Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benedikt Pulver

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Drug Testing and Analysis|November 8, 2022
EMCDDA framework and practical guidance for naming synthetic cannabinoidsBenedikt Pulver, Svenja Fischmann, Ana Gallegos, et al.
Drug Testing and Analysis|February 23, 2024
EMCDDA framework and practical guidance for naming cathinonesBenedikt Pulver, Svenja Fischmann, Ana Gallegos, et al.
Metabolites|December 23, 2022
In Vitro and In Vivo Toxicometabolomics of the Synthetic Cathinone PCYP Studied by Means of LC-HRMS/MSSelina Hemmer, Lea Wagmann, Benedikt Pulver, et al.
Drug Testing and Analysis|July 11, 2023
Pharmacological profile, phase I metabolism, and excretion time profile of the new synthetic cathinone 3,4-Pr-PipVPHannes Max Schwelm, Mattias Persson, Benedikt Pulver, et al.
Toxicology|July 16, 2022
A simplified strategy to assess the cytotoxicity of new psychoactive substances in HepG2 cells using a high content screening assay - Exemplified for nine compoundsTanja M Gampfer, Lea Wagmann, Benedikt Pulver, et al.
Drug Testing and Analysis|September 1, 2024
Human phase-I metabolism of three synthetic cannabinoids bearing a cumyl moiety and a cyclobutyl methyl or norbornyl methyl tail: Cumyl-CBMEGACLONE, Cumyl-NBMEGACLONE, and Cumyl-NBMINACAArianna Giorgetti, Pietro Brunetti, Belal Haschimi, et al.
Journal of Analytical Toxicology|March 5, 2024
Insights into the metabolism of CH-PIATA-A novel synthetic cannabinoid featuring an acetamide linkerAnnette Zschiesche, Martin Scheu, Detlef Thieme, et al.
Drug Testing and Analysis|April 3, 2024
Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)Pierce V Kavanagh, Folker Westphal, Benedikt Pulver, et al.
Drug Testing and Analysis|September 22, 2022
A new synthetic cathinone: 3,4-EtPV or 3,4-Pr-PipVP? An unsuccessful attempt to circumvent the German legislation on new psychoactive substancesBenedikt Pulver, Jan Riedel, Folker Westphal, et al.
Drug Testing and Analysis|November 27, 2021
Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Drug Testing and Analysis|November 8, 2022
EMCDDA framework and practical guidance for naming synthetic cannabinoidsBenedikt Pulver, Svenja Fischmann, Ana Gallegos, et al.
Drug Testing and Analysis|February 23, 2024
EMCDDA framework and practical guidance for naming cathinonesBenedikt Pulver, Svenja Fischmann, Ana Gallegos, et al.
Metabolites|December 23, 2022
In Vitro and In Vivo Toxicometabolomics of the Synthetic Cathinone PCYP Studied by Means of LC-HRMS/MSSelina Hemmer, Lea Wagmann, Benedikt Pulver, et al.
Drug Testing and Analysis|July 11, 2023
Pharmacological profile, phase I metabolism, and excretion time profile of the new synthetic cathinone 3,4-Pr-PipVPHannes Max Schwelm, Mattias Persson, Benedikt Pulver, et al.
Toxicology|July 16, 2022
A simplified strategy to assess the cytotoxicity of new psychoactive substances in HepG2 cells using a high content screening assay - Exemplified for nine compoundsTanja M Gampfer, Lea Wagmann, Benedikt Pulver, et al.
Drug Testing and Analysis|September 1, 2024
Human phase-I metabolism of three synthetic cannabinoids bearing a cumyl moiety and a cyclobutyl methyl or norbornyl methyl tail: Cumyl-CBMEGACLONE, Cumyl-NBMEGACLONE, and Cumyl-NBMINACAArianna Giorgetti, Pietro Brunetti, Belal Haschimi, et al.
Journal of Analytical Toxicology|March 5, 2024
Insights into the metabolism of CH-PIATA-A novel synthetic cannabinoid featuring an acetamide linkerAnnette Zschiesche, Martin Scheu, Detlef Thieme, et al.
Drug Testing and Analysis|April 3, 2024
Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)Pierce V Kavanagh, Folker Westphal, Benedikt Pulver, et al.
Drug Testing and Analysis|September 22, 2022
A new synthetic cathinone: 3,4-EtPV or 3,4-Pr-PipVP? An unsuccessful attempt to circumvent the German legislation on new psychoactive substancesBenedikt Pulver, Jan Riedel, Folker Westphal, et al.
Drug Testing and Analysis|November 27, 2021
Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Pageof 3